keyword
MENU ▼
Read by QxMD icon Read
search

Active surveillance prostate

keyword
https://www.readbyqxmd.com/read/28728993/value-of-tracking-biopsy-in-men-undergoing-active-surveillance-of-prostate-cancer
#1
Edward Chang, Tonye A Jones, Shyam Natarajan, Devi Sharma, Demetrios Simopoulos, Daniel J Margolis, Jiaoti Huang, Frederick J Dorey, Leonard S Marks
PURPOSE: To compare the upgrading rate obtained by re-sampling precise spots of prostate cancer (tracking biopsy) vs conventional systematic re-sampling, during follow-up of; men in active surveillance. MATERIALS AND METHODS: Subjects were all 352 men, from 2009 to 2017, with Gleason 3+3 (n=268) or Gleason 3+4 (n=84) prostate cancer at initial MRI/ultrasound fusion biopsy and who subsequently had a second fusion biopsy. At first biopsy session, all men underwent 12-core systematic biopsies and, when MRI-visible lesions were present, targeted biopsies...
July 17, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28725591/diffusion-weighted-imaging-of-the-prostate-principles-application-and-advances
#2
REVIEW
Martin H Maurer, Johannes T Heverhagen
This review article aims to provide an overview on the principles of diffusion-weighted magnetic resonance imaging (DW-MRI) and its applications in the imaging of the prostate. DW-MRI with regards to different applications for prostate cancer (PCa) detection and characterization, local staging as well as for active surveillance (AS) and tumor recurrence after radical prostatectomy (RP) will be discussed. Furthermore, advances in DW-MRI techniques like diffusion kurtosis imaging (DKI) will be presented.
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28725590/mri-fusion-biopsy-the-contemporary-experience
#3
REVIEW
Marc A Bjurlin, Andrew B Rosenkrantz, Samir S Taneja
Advancements in magnetic resonance imaging (MRI) and MRI-ultrasound (US)-fusion targeted biopsy have resulted in a paradigm shift in the diagnosis of prostate cancer by overcoming the limitations of systematic biopsy. Prebiopsy MRI and MRI-US-fusion biopsy results in an increased detection of clinically significant disease, reduction in the detection of indolent disease, and allows for tumor localization during targeted biopsy. With these advantages, we have adopted a prebiopsy MRI and MRI-US-fusion biopsy diagnostic care pathway for all men at risk for prostate cancer and have performed more than 1900 biopsies to date...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28725589/multi-parametric-magnetic-resonance-imaging-as-a-management-decision-tool
#4
REVIEW
David C Johnson, Robert E Reiter
The ability to image the prostate accurately and better characterize cancerous lesions makes multiparametric magnetic resonance imaging (mpMRI) an invaluable tool to improve management of localized prostate cancer (PCa). Improved risk stratification is warranted given the evidence of significant overtreatment of indolent PCa. mpMRI can more accurately rule out clinically significant PCa in men deciding between surveillance and definitive treatment to reduce overtreatment. mpMRI improves detection of clinically significant PCa, which helps minimize sampling error, a major limitation of the traditional diagnostic paradigm...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28725588/role-of-mpmri-of-the-prostate-in-screening-for-prostate-cancer
#5
REVIEW
Christopher J D Wallis, Masoom A Haider, Robert K Nam
Prostate cancer screening offers the opportunity to significantly reduce morbidity and mortality from this disease. Currently, serum prostate-specific antigen (PSA) testing is the most widely used screening modality. However, PSA testing continues to have low positive and negative predictive value leading to unnecessary invasive prostate biopsy while missing patients with aggressive forms of the disease. Magnetic resonance imaging (MRI) has been gaining an increasingly large role in the management of patients with early stage prostate cancer including diagnosis in patients with abnormal PSA levels, monitoring of patients on active surveillance, and staging prior to definitive interventions...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28725586/role-of-prostate-magnetic-resonance-imaging-in-active-surveillance
#6
REVIEW
Xiaosong Meng, Andrew B Rosenkrantz, Samir S Taneja
Active surveillance (AS) has emerged as a beneficial strategy for management of low risk prostate cancer (PCa) and prevention of overtreatment of indolent disease. However, selection of patients for AS using traditional 12-core transrectal prostate biopsy is prone to sampling error and presents a challenge for accurate risk stratification. In fact, around a third of men are upgraded on repeat biopsy which disqualifies them as appropriate AS candidates. This uncertainty affects adoption of AS among patients and physicians, leading to current AS protocols involving repetitive prostate biopsies and unclear triggers for progression to definitive treatment...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28725581/direct-magnetic-resonance-imaging-guided-biopsy-of-the-prostate-lessons-learned-in-establishing-a-regional-referral-center
#7
REVIEW
Benjamin Addicott, Bryan R Foster, Chenara Johnson, Alice Fung, Christopher L Amling, Fergus V Coakley
MRI-targeted biopsy of the prostate appears to have the potential to reduce the high rates of underdiagnosis and overdiagnosis associated with the current diagnostic standard of transrectal ultrasound guided systematic biopsy. Direct or "in bore" MRI-guided biopsy is one of the three methods for MRI-targeted core needle sampling of suspicious, generally Pi-RADS 4 or 5, foci within the prostate, and our early experience suggests the approach demonstrates substantial utility and promise in the care of patients with prostate cancer...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28725579/multiparametric-magnetic-resonance-imaging-of-the-prostate-a-basic-tutorial
#8
REVIEW
Miguel C Cabarrus, Antonio C Westphalen
Prostate cancer is the second most common cause of cancer related death in the United States and the most commonly diagnosed malignancy in men. In general, prostate cancer is slow growing, though there is a broad spectrum of disease that may be indolent, or aggressive and rapidly progressive. Screening for prostate is controversial and complicated by lack of specificity and over diagnosis of clinically insignificant cancer. Imaging has played a role in diagnosis of prostate cancer, primarily through systemic transrectal ultrasound (TRUS) guided biopsy...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28725576/cost-consideration-in-utilization-of-multiparametric-magnetic-resonance-imaging-in-prostate-cancer
#9
REVIEW
Ryan Hutchinson, Yair Lotan
The screening, evaluation and management of prostate cancer changed significantly in the last decade. The recommendations regarding prostate cancer screening continue to evolve with new revelations about existing data sets and longer followup of landmark trials. Robotics has gained the vast majority of the marketplace for surgically managed prostate cancer in rapid fashion. The need for intervention in low risk prostate cancer has been closely examined and more men are being expectantly managed than ever before...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28715578/adverse-pathologic-findings-for-men-electing-immediate-radical-prostatectomy-defining-a-favorable-intermediate-risk-group
#10
Hiten D Patel, Jeffrey J Tosoian, H Ballentine Carter, Jonathan I Epstein
Importance: Active surveillance is recommended for patients with very low-risk (VLR) and low-risk (LR) prostate cancer. Despite controversy, recent clinical guidelines state surveillance may be considered for men with low-volume intermediate-risk (LVIR) disease. Objective: To compare rates of adverse pathologic findings among VLR, LR, and LVIR men electing immediate radical prostatectomy and evaluate criteria to define if a favorable intermediate-risk group minimizing risk exists...
July 13, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28713796/multimodal-imaging-in-focal-therapy-planning-and-assessment-in-primary-prostate-cancer
#11
Hossein Jadvar
PURPOSE: There is increasing interest in focal therapy (male lumpectomy) of localized low-intermediate risk prostate cancer. Focal therapy is typically associated with low morbidity and provides the possibility of retreatment. Imaging is pivotal in stratification of men with localized prostate cancer for active surveillance, focal therapy or radical intervention. This article provides a concise review of focal therapy and the evolving role of imaging in this clinical setting. METHODS: We performed a narrative and critical literature review by searching PubMed/Medline database from January 1997 to January 2017 for articles in the English language and the use of search keywords "focal therapy", "prostate cancer", and "imaging"...
June 2017: Clinical and Translational Imaging: Reviews in Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28710901/baseline-and-longitudinal-plasma-caveolin-1-level-as-a-biomarker-in-active-surveillance-for-early-stage-prostate-cancer
#12
Spyridon P Basourakos, John W Davis, Brian F Chapin, John F Ward, Curtis A Pettaway, Louis L Pisters, Neema Navai, Mary F Achim, Xuemei Wang, Hsiang-Chun Chen, Seungtaek Choi, Deborah Kuban, Patricia Troncoso, Sam Hanash, Timothy C Thompson, Jeri Kim
OBJECTIVES: To evaluate the role of caveolin-1 as a predictor of disease reclassification in men with early prostate cancer undergoing active surveillance. PATIENTS AND METHODS: We analyzed archived plasma samples prospectively collected from men with early prostate cancer in a single-institution active surveillance study. Of 825 patients enrolled, 542 had 1 or more years of follow-up. Baseline and longitudinal plasma caveolin-1 levels were measured using an enzyme-linked immunosorbent assay...
July 15, 2017: BJU International
https://www.readbyqxmd.com/read/28707808/cytotoxic-necrotizing-factor-1-promotes-prostate-cancer-progression-through-activating-the-cdc42-pak1-axis
#13
Yaxiu Guo, Zhisong Zhang, Huiting Wei, Jingyu Wang, Junqiang Lv, Kai Zhang, Evan T Keller, Zhi Yao, Quan Wang
Uropathogenic Escherichia coli (UPEC) is the leading cause of urinary tract infections and plays a role in prostatic carcinogenesis and prostate cancer (PCa) progression. However, the mechanisms through which UPEC promotes PCa development and progression are unclear. Cytotoxic necrotizing factor 1 (CNF1) is one of the most important UPEC toxins and its role in PCa progression has never been studied. We found that UPEC-secreted CNF1 promoted the migration and invasion of PCa cells and PCa metastasis. In vitro studies showed that CNF1 promotes pro-migratory and pro-invasive activity through entering PCa cells and activating Cdc42, which subsequently induced PAK1 phosphorylation and upregulation of MMP-9 expression...
July 14, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28695317/pre-radiotherapy-psa-progression-is-a%C3%A2-negative-prognostic-factor-in-prostate-cancer-patients-using-5%C3%A2-alpha-reductase-inhibitors
#14
Daniel Taussky, Julie Piotte, Kevin C Zorn, Marc Zanaty, Vimal Krishnan, Carole Lambert, Jean-Paul Bahary, Marie-Claude Beauchemin, Maroie Barkati, Cynthia Ménard, Guila Delouya
OBJECTIVE: To investigate the impact of 5‑alpha-reductase inhibitor (5-ARI) use on radiotherapy outcomes for localized prostate cancer. PATIENTS AND METHODS: We included 203 patients on a 5-ARI from our institutional database comprising over 2500 patients who had been treated with either external beam radiotherapy (EBRT) or brachytherapy for localized prostate cancer. Patients received a 5-ARI for urinary symptoms or active surveillance. Cancer progressions at the time of definitive treatment were analyzed according to the following criteria: (a) progression of Gleason score or increase in cancer volume on biopsy, (b) first biopsy positive for cancer after being treated for urinary symptoms with a 5-ARI, and (c) prostate-specific antigen (PSA) progression with or without a previous cancer diagnosis...
July 10, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28678408/longitudinal-regret-after-treatment-for-low-and-intermediate-risk-prostate-cancer
#15
Lauren M Hurwitz, Jennifer Cullen, Daniel J Kim, Sally Elsamanoudi, Jane Hudak, Maryellen Colston, Judith Travis, Huai-Ching Kuo, Kevin R Rice, Christopher R Porter, Inger L Rosner
BACKGROUND: Prostate cancer patients diagnosed with low- and intermediate-risk disease have several treatment options. Decisional regret after treatment is a concern, especially when poor oncologic outcomes or declines in health-related quality of life (HRQoL) occur. This study assessed determinants of longitudinal decisional regret in prostate cancer patients attending a multidisciplinary clinic and treated with radical prostatectomy (RP), external beam radiation therapy (EBRT), brachytherapy (BT), or active surveillance (AS)...
July 5, 2017: Cancer
https://www.readbyqxmd.com/read/28677001/incidental-findings-on-multiparametric-mri-performed-for-evaluation-of-prostate-cancer
#16
Rachael L Sherrer, Win Shun Lai, John V Thomas, Jeffrey W Nix, Soroush Rais-Bahrami
PURPOSE: Multiparametric magnetic resonance imaging (mp-MRI) and MRI/Ultrasound (US) fusion-guided biopsy are relatively new techniques for improved detection, staging, and active surveillance of prostate cancer (PCa). As with all imaging modalities, MRI reveals incidental findings (IFs) which carry the risk of increased cost, patient anxiety, and iatrogenic morbidity due to workup of IFs. Herein, we report the IFs from 684 MRIs for evaluation of PCa and consider their characteristics and clinical significance...
July 4, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28673277/impact-of-a-protein-based-assay-that-predicts-prostate-cancer-aggressiveness-on-urologists-recommendations-for-active-treatment-or-active-surveillance-a-randomized-clinical-utility-trial
#17
John W Peabody, Lisa M DeMaria, Diana Tamondong-Lachica, Jhiedon Florentino, M Czarina Acelajado, Othman Ouenes, Jerome P Richie, Trever Burgon
BACKGROUND: Of the more than 1.1 million men diagnosed worldwide annually with prostate cancer, the majority have indolent tumors. Distinguishing between aggressive and indolent cancer is an important clinical challenge. The current approaches for assessing tumor aggressiveness are recognized as insufficient. A validated protein-based assay has been shown to predict tumor aggressiveness from prostate biopsy. The main objective of this study was to measure the clinical utility of this new assay in the management of early-stage prostate cancer...
July 3, 2017: BMC Urology
https://www.readbyqxmd.com/read/28655021/the-diagnosis-and-treatment-of-prostate-cancer-a-review
#18
REVIEW
Mark S Litwin, Hung-Jui Tan
Importance: Prostate cancer is the most common cancer diagnosis made in men with more than 160 000 new cases each year in the United States. Although it often has an indolent course, prostate cancer remains the third-leading cause of cancer death in men. Observations: When prostate cancer is suspected, tissue biopsy remains the standard of care for diagnosis. However, the identification and characterization of the disease have become increasingly precise through improved risk stratification and advances in magnetic resonance and functional imaging, as well as from the emergence of biomarkers...
June 27, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28651567/benefits-and-harms-of-prostate-cancer-screening-predictions-of-the-oncotyrol-prostate-cancer-outcome-and-policy-model
#19
Nikolai Mühlberger, Kristijan Boskovic, Murray D Krahn, Karen E Bremner, Willi Oberaigner, Helmut Klocker, Wolfgang Horninger, Gaby Sroczynski, Uwe Siebert
BACKGROUND: A recent recalibration of the ONCOTYROL Prostate Cancer Outcome and Policy (PCOP) Model, assuming that latent prostate cancer (PCa) detectable at autopsy might be detectable by screening as well, resulted in considerable worsening of the benefit-harm balance of screening. In this study, we used the recalibrated model to assess the effects of familial risk, quality of life (QoL) preferences, age, and active surveillance. METHODS: Men with average and elevated familial PCa risk were simulated in separate models, differing in familial risk parameters...
June 26, 2017: BMC Public Health
https://www.readbyqxmd.com/read/28644154/acute-promyelocytic-leukemia-and-chronic-lymphocytic-leukemia-concomitant-presentation-of-two-molecularly-distinct-entities
#20
Jingdong Su, Diana Veillon, Rodney Shackelford, James Cotelingam, Hazem El-Osta, Glenn Mills, Reinhold Munker, Srinivas Devarakonda
Acute myeloid leukemia (AML) developing in patients with chronic lymphocytic leukemia (CLL) is very uncommon and usually associated with prior treatment. Acute promyelocytic leukemia (APL) accounts for a very small proportion of treatment-associated AML. So far, there has been only one reported case of APL occurring post radiation for prostate cancer in a patient with CLL. We report herein the first case of APL and CLL presenting concomitantly in an untreated patient. Evaluation of peripheral blood and bone marrow aspirate with immunohistochemistry, flow cytometry, and FISH to confirm two morphologically, molecularly and genetically distinct leukemic populations characteristic of APL and CLL is required...
May 2017: Journal of the Louisiana State Medical Society: Official Organ of the Louisiana State Medical Society
keyword
keyword
109735
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"